Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of LY4101174 in recurrent, advanced, or metastatic solid tumors
jRCT2031240083Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of ETx-22 in transitional cell carcinoma (TCC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and 8 more (9 arms), sponsored by Eli Lilly and Company. Primary endpoints: Recommended dose determination, Recommended phase 2 dose or optimal dose determination and 1 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
ETx-22
03
Conditions
transitional cell carcinoma (TCC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)esophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2031240083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240083.